Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | PARG | Q86W56 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18949108 | 0.84 | KDM4E (0.38) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL23815613 | 0.82 | KDM4E (0.36) | KDM4EHSD17B10LMNAALDH1A1PARG | |
| SCHEMBL5990747 | 0.81 | KDM4E (0.43) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL25049622 | 0.80 | ADORA3 (0.38) | KDM4ECYP1A2SCN10AADORA3 | |
| SCHEMBL23675588 | 0.79 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL18949090 | 0.77 | KDM4E (0.40) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL12232006 | 0.77 | KDM4E (0.40) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL12938120 | 0.75 | KDM4E (0.48) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL15471951 | 0.75 | LMNA (0.34) | KDM4ELMNAALDH1A1 | |
| SCHEMBL12294460 | 0.75 | KDM4E (0.39) | KDM4EHSD17B10LMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| WO-2023133284-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2022150555-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-7935530-B2 | Selectively bind DNA and entering nucleus of cells; for modulating gene expression in cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-05-03 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-7713701-B2 | DNA-binding polymers | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090155202-A1 | DNA-BINDING POLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2009-06-18 | — | — | US | disclosed |
| US-7452730-B2 | DNA-binding polymers | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080269138-A1 | Polyamides with tail structures | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KDM4E 2318/4885HSD17B10 2002/4885LMNA 3118/4885 |
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KDM4E 2318/4885HSD17B10 2002/4885LMNA 3118/4885 |
| US-20080269138-A1 | Polyamides with tail structures | HNRNPH3, PCNA, DNAH12 | KDM4E 1338/4885HSD17B10 1919/4885LMNA 533/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDM4E 4095/4885HSD17B10 1287/4885LMNA 1249/4885 |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KDM4E 1193/4885HSD17B10 581/4885LMNA 2800/4885 |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | KDM4E 1581/4885HSD17B10 3176/4885LMNA 4094/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KDM4E 2603/4885HSD17B10 3834/4885LMNA 2020/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | KDM4E 4219/4885HSD17B10 1268/4885LMNA 2015/4885 |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | KDM4E 1321/4885HSD17B10 1474/4885LMNA 886/4885 |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | CYFIP2, TPX2, CYFIP1 | KDM4E 1660/4885HSD17B10 3388/4885LMNA 1622/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KDM4E 1193/4885HSD17B10 581/4885LMNA 2800/4885 |
| US-20090155202-A1 | DNA-BINDING POLYMERS | PCNA, DDB1, TOP2A | KDM4E 2859/4885HSD17B10 3317/4885LMNA 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.